Compass Therapeutics, Inc. (CMPX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$0.87

From 52W high−87.52%

Volume3.11M

Market cap$150.37M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$0.87

From 52W high

−87.52%

Volume

3.11M

Market cap

$150.37M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.3x

P/E (TTM)

—

RSI (14)

24.3

MomentumView details →

1D Return

−2.91%

YTD Return

−84.31%

SummaryUpdated Jun 1, 2026

Compass Therapeutics, Inc. (NASDAQ:CMPX) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Boston, Massachusetts. The company went public in April 2021 and focuses on developing innovative antibody-based therapeutics for cancer treatment. As a pre-revenue biotechnology firm, Compass is currently advancing multiple drug candidates through various phases of clinical trials, with a particular emphasis on novel approaches to oncology treatment through bispecific antibodies and immune system modulators.

Ask drillr about Compass Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−44.23%

ROA (TTM)

−38.62%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+6.99%

FCF YoY

−21.49%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

−16.67%

EBITDA YoY

−12.84%

MomentumView details →

1D Return

−2.91%

YTD Return

−84.31%

1Y Return

−79.20%

RSI (14)

24.3

vs 50D SMA

−51.56%

vs 200D SMA

−75.19%

Capital & dividendView details →

Debt/Equity

0.06x

Current Ratio

11.22x

Quick Ratio

11.22x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.13

EPS Surprise

−17.47%

Beats (12Q)

5/12

Next Q EPS Est

−$0.14

Avg Surprise (4Q)

7.40%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−73.45M

Op. CF (TTM)

−54.79M

Next earningsNov 4, 2026 →

Latest newsMore news →

Compass Therapeutics reported a net loss of $25.2 million for Q2 2026, with diluted EPS of -$0.13, and held $180 million in cash and marketable securities at quarter end.75d ago

Similar companies

NovaBridge BiosciencesNBP Coherus Oncology, Inc.CHRS Upstream Bio, Inc.UPB Adagene Inc.ADAG Pyxis Oncology, Inc.PYXS Jyong Biotech Ltd. Ordinary SharesMENS Find similar companies →

Latest newsMore news →

Compass Therapeutics reported a net loss of $25.2 million for Q2 2026, with diluted EPS of -$0.13, and held $180 million in cash and marketable securities at quarter end.75d ago